These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20146242)

  • 21. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management.
    Sokol KC; Knudsen JF; Li MM
    J Clin Pharm Ther; 2007 Apr; 32(2):169-75. PubMed ID: 17381667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline laboratory monitoring of cardiovascular medications in elderly health maintenance organization enrollees.
    Simon SR; Andrade SE; Ellis JL; Nelson WW; Gurwitz JH; Lafata JE; Davis RL; Feldstein A; Raebel MA
    J Am Geriatr Soc; 2005 Dec; 53(12):2165-9. PubMed ID: 16398903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular drug therapy in the elderly.
    Aronow WS; Frishman WH; Cheng-Lai A
    Cardiol Rev; 2007; 15(4):195-215. PubMed ID: 17575484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morbidity, mortality and economic burden of renal impairment in cardiac intensive care.
    Chew DP; Astley C; Molloy D; Vaile J; De Pasquale CG; Aylward P
    Intern Med J; 2006 Mar; 36(3):185-92. PubMed ID: 16503954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic implications of the gender-specific aspects of cardiovascular disease.
    Regitz-Zagrosek V
    Nat Rev Drug Discov; 2006 May; 5(5):425-38. PubMed ID: 16672926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Problems and pitfalls in cardiac drug therapy.
    Stone SM; Rai N; Nei J
    Rev Cardiovasc Med; 2001; 2(3):126-42. PubMed ID: 12439377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular drugs and the elderly population.
    Lapinski ML
    Heart Lung; 1982; 11(5):430-4. PubMed ID: 6921190
    [No Abstract]   [Full Text] [Related]  

  • 28. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.
    Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
    Am J Cardiovasc Drugs; 2010; 10(2):85-94. PubMed ID: 20334445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece.
    Alexopoulou A; Dourakis SP; Mantzoukis D; Pitsariotis T; Kandyli A; Deutsch M; Archimandritis AJ
    Eur J Intern Med; 2008 Nov; 19(7):505-10. PubMed ID: 19013378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse dermatologic effects of cardiovascular drug therapy.
    Brosnan BD; Frishman WH; Sun DK; Grossman M
    Heart Dis; 2000; 2(3):220-47. PubMed ID: 11728264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Adverse internal medicine drug effects at hospital admission].
    Lepori V; Perren A; Marone C
    Schweiz Med Wochenschr; 1999 Jun; 129(24):915-22. PubMed ID: 10413826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A population-based study on well-being in the very old: the role of cardiovascular diseases and drugs.
    Westerbotn M; Agüero-Torres H; Fastbom J; Hillerås P
    Arch Gerontol Geriatr; 2005; 40(3):287-97. PubMed ID: 15814162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [An analysis of pharmacotherapy in an internal medicine ambulatory care clinic, using the example of cardiovascular-effective drugs].
    Conen D; Zschokke U; Dubach UC
    Schweiz Med Wochenschr; 1981 Aug; 111(31-32):1163-8. PubMed ID: 7280625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit.
    Winning J; Neumann J; Kohl M; Claus RA; Reinhart K; Bauer M; Lösche W
    Crit Care Med; 2010 Jan; 38(1):32-7. PubMed ID: 19770746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Retrospective analysis of adverse cutaneous drug reactions in patients hospitalized in Department of Dermatology and Venereology of Pomeranian Medical University in 1996-2006].
    Kacalak-Rzepka A; Klimowicz A; Bielecka-Grzela S; Załuga E; Maleszka R; Fabiańczyk H
    Ann Acad Med Stetin; 2008; 54(2):52-8. PubMed ID: 19374232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse drug reactions in patients with cardiovascular disease. Foreword.
    Rahimtoola SH
    Curr Probl Cardiol; 2008 Dec; 33(12):701. PubMed ID: 19000585
    [No Abstract]   [Full Text] [Related]  

  • 37. Prevalence of risk factors of ST segment elevation myocardial infarction in Turkish patients living in Central Anatolia.
    Aygül N; Ozdemir K; Abaci A; Aygül MU; Düzenli MA; Vatankulu MA; Yazici HU; Ozdoğru I; Karakaya E
    Anadolu Kardiyol Derg; 2009 Feb; 9(1):3-8. PubMed ID: 19196566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Epidemiology and prevention of cardiovascular diseases].
    Jánosi A
    Orv Hetil; 2005 Apr; 146(15):683-8. PubMed ID: 15895792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cardiovascular drugs poisoning in the elderly patients hospitalized in the Province Poisoning Center in Lublin in the years 1995-2001].
    Lewandowska-Stanek H; Gołacka E; Niewiedzioł M
    Przegl Lek; 2002; 59(4-5):336-8. PubMed ID: 12184001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
    Portolés J; López-Gómez JM; Aljama P
    Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.